Loading organizations...
§ Private Profile · Shanghai, Shanghai, China
Zhenge Biotech is a technology company.
Zhenge Biotech, operating as Zencore Biologics, is a Contract Development and Manufacturing Organization (CDMO) that provides comprehensive services for large molecule biologics. The company offers a one-stop solution covering biologics and Antibody-Drug Conjugate (ADC) development and manufacturing, alongside expertise in cell culture media production, advanced analytical services, and regulatory support. Its technical approach centers on developing efficient and robust manufacturing processes to deliver high-quality clinical and commercial biological products.
Jianxin Chen founded Zhenge Biotech in November 2017, establishing the company based on the insight into the increasing need for specialized external capabilities in the complex landscape of macromolecular biopharmaceutical development and production. Under Chen’s guidance, the company quickly established itself as a key partner in the biopharmaceutical industry.
Zencore Biologics serves pharmaceutical and biotechnology companies globally, assisting them throughout their drug development pipelines. The company's mission is to foster a healthier world by providing top-tier research, development, and manufacturing services for biologics. Its vision is to continue advancing therapeutic solutions to meet the evolving needs of patients worldwide.
Zhenge Biotech has raised $170.0M across 2 funding rounds.
Zhenge Biotech has raised $170.0M in total across 2 funding rounds.
Zhenge Biotech has raised $170.0M across 2 funding rounds. Most recently, it raised $100.0M Series C in January 2022.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jan 1, 2022 | $100M Series C | Kevin XU, Xiao Tian LOI | Qiming Venture Partners, IDG Capital, Junxin Capital, Lyfe Capital, Amit Kakar MD | Announced |
| Mar 1, 2021 | $70M Series B | Qiming Venture Partners, IDG Capital | — | Announced |
Zhenge Biotech has raised $170.0M in total across 2 funding rounds.
Zhenge Biotech's investors include Kevin Xu, Xiao-Tian Loi, Qiming Venture Partners, IDG Capital, Junxin Capital, LYFE Capital, Amit Kakar MD.
ZhenGe Biotech is a contract development and manufacturing organization (CDMO) specializing in integrated services for biologics, from pre-clinical research to commercial manufacturing, including customized cell culture media development. It serves biotech and pharmaceutical companies worldwide, enabling the R&D and commercialization of innovative biologics like monoclonal and bispecific antibodies, with expertise in large-scale animal cell culture technology for macromolecular drugs.[1][3][4] Established in 2017 as a high-tech enterprise in Shanghai's China Pilot Free Trade Zone, the company has grown rapidly to around 600 employees, raised over $190 million in funding (including a $100 million Series C led by Goldman Sachs Asset Management and Sofina), and operates development centers in Shanghai and Maryland (via subsidiary Zencore Bio), plus cGMP manufacturing in Shanghai.[1][2][3][6]
The company solves critical bottlenecks in biologics production by offering end-to-end CDMO solutions, accelerating timelines for clients developing therapies for diseases like oncology and immunology. Growth momentum includes European expansion with a €1 million investment in a Limburg, Belgium branch to tap into the local pharma ecosystem, alongside strong revenue ($151.9 million reported) and multiple funding rounds signaling investor confidence.[2][3]
Founded in 2017, Shanghai ZhenGe Biotechnology Co., Ltd. (ZhenGe Biotech) emerged in Shanghai's China Pilot Free Trade Zone as a high-tech enterprise focused on filling gaps in biologics CDMO services.[1][3] Specific founders are not detailed in available sources, but the company quickly built capabilities in mammalian cell culture media and macromolecular biopharmaceuticals, establishing development centers in Shanghai, an innovation center in Maryland (Zencore Bio), and cGMP sites in Shanghai.[1]
Early traction came from its integrated model supporting over 100 pharmaceutical clients, leading to rapid scaling with 600 employees by recent years and a $100 million Series C in 2021 led by Goldman Sachs Asset Management and Sofina. A pivotal moment was its 2023 European entry via a €1 million investment in Belgium's Health Campus in Limburg, signed at BIO International Convention, marking its shift from Asia-U.S. focus to global expansion amid booming biologics demand.[2][6]
ZhenGe Biotech rides the explosive growth in biologics and advanced therapies, where demand for monoclonal antibodies and cell-based drugs surges due to oncology, immunology, and rare disease treatments. Its timing aligns with global CDMO capacity shortages post-COVID, as pharma outsources complex manufacturing amid supply chain pressures.[1][2] Market forces like rising R&D investments in biologics (projected multi-billion market) and regional hubs (e.g., U.S., China, Europe) favor its multi-continental model, bridging Eastern manufacturing scale with Western innovation.[2][3]
The company influences the ecosystem by accelerating 100+ client pipelines, fostering biotech hubs like Limburg's Health Campus alongside players like Amador Bioscience, and investing in market research to shape CDMO trends. This positions ZhenGe as a key enabler in democratizing access to high-end biologics production for smaller biotechs.[1][2]
ZhenGe Biotech is poised for accelerated global scaling, with its Belgium foothold signaling further European production builds and potential acquisitions to expand capacity. Trends like AI-driven drug discovery, bispecific antibodies, and personalized medicine will amplify demand for its cell culture and CDMO expertise, potentially doubling revenue amid biologics market growth.[2][3] Influence may evolve toward leading Asia-Europe-U.S. bridges, powering more breakthrough therapies—cementing its role as a cornerstone for the next wave of biotech innovation, much like its origins in Shanghai's free trade zone fueled its rise.